Rod-derived cone viability factor for treating blinding diseases: From clinic to redox signaling

Science Translational Medicine

Volumn 2, Issue 26, 2010, Pages

  Léveillard, Thierry ^a   Sahel, José Alain ^a,b,c,d  

^a INSTITUT DE LA VISION   (France)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EYE PROTEIN; NUCLEOREDOXIN LIKE PROTEIN 1; NUCLEOREDOXIN LIKE PROTEIN 2; PHOSPHODIESTERASE VI; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN RPE65; REGULATOR PROTEIN; ROD DERIVED CONE VIABILITY FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRL; UNCLASSIFIED DRUG; VIRUS VECTOR; THIOREDOXIN;

BLINDNESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; EYE PROTECTION; GENE DELIVERY SYSTEM; GENE MUTATION; GENE THERAPY; GENETIC IDENTIFICATION; HUMAN; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CONE; RETINA DEGENERATION; RETINA ROD; RETINITIS PIGMENTOSA; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; ANIMAL; CELL SURVIVAL; GENETICS; METABOLISM; MOUSE; RETINAL DEGENERATION; RETINAL DISEASES; TRANSLATIONAL RESEARCH;

ANIMALS; BLINDNESS; CELL SURVIVAL; HUMANS; MICE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL DEGENERATION; RETINAL DISEASES; RETINAL ROD PHOTORECEPTOR CELLS; SIGNAL TRANSDUCTION; THIOREDOXINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 77952962177     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000866     Document Type: Review

References (31)

1. F. Simonelli, A. M. Maguire, F. Testa, E. A. Pierce, F. Mingozzi, J. L. Bennicelli, S. Rossi, K. Marshall, S. Banfi, E. M. Surace, J. Sun, T. M. Redmond, X. Zhu, K. S. Shindler, G. S. Ying, C. Ziviello, C. Acerra, J. F. Wright, J. W. McDonnell, K. A. High, J. Bennett, A. Auricchio, Gene therapy for Leber's congenital amaurosis is safe and effective through 1. 5 years after vector administration. Mol. Ther. 18, 643-650 (2010).
2. C. P. Hamel, E. Tsilou, B. A. Pfeffer, J. J. Hooks, B. Detrick, T. M. Redmond, Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J. Biol. Chem. 268, 15751-15757 (1993).
3. F. Marlhens, C. Bareil, J. M. Griffoin, E. Zrenner, P. Amalric, C. Eliaou, S. Y. Liu, E. Harris, T. M. Redmond, B. Arnaud, M. Claustres, C. P. Hamel, Mutations in RPE65 cause Leber's congenital amaurosis. Nat. Genet. 17, 139-141 (1997).
4. S. M. Gu, D. A. Thompson, C. R. Srikumari, B. Lorenz, U. Finckh, A. Nicoletti, K. R. Murthy, M. Rathmann, G. Kumaramanickavel, M. J. Denton, A. Gal, Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat. Genet. 17, 194-197 (1997).
5. G. D. Aguirre, V. Baldwin, S. Pearce-Kelling, K. Narfström, K. Ray, G. M. Acland, Congenital stationary night blindness in the dog: Common mutation in the RPE65 gene indicates founder effect. Mol. Vis. 4, 23 (1998).
6. G. M. Acland, G. D. Aguirre, J. Ray, Q. Zhang, T. S. Aleman, A. V. Cideciyan, S. E. Pearce-Kelling, V. Anand, Y. Zeng, A. M. Maguire, S. G. Jacobson, W. W. Hauswirth, J. Bennett, Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95 (2001).
7. A. M. Maguire, F. Simonelli, E. A. Pierce, E. N. Pugh Jr., F. Mingozzi, J. Bennicelli, S. Banfi, K. A. Marshall, F. Testa, E. M. Surace, S. Rossi, A. Lyubarsky, V. R. Arruda, B. Konkle, E. Stone, J. Sun, J. Jacobs, L. Dell'Osso, R. Hertle, J. X. Ma, T. M. Redmond, X. Zhu, B. Hauck, O. Zelenaia, K. S. Shindler, M. G. Maguire, J. F. Wright, N. J. Volpe, J. W. McDonnell, A. Auricchio, K. A. High, J. Bennett, Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248 (2008).
8. J. W. Bainbridge, A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, G. E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S. S. Bhattacharya, A. J. Thrasher, F. W. Fitzke, B. J. Carter, G. S. Rubin, A. T. Moore, R. R. Ali, Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239 (2008).
9. A. V. Cideciyan, T. S. Aleman, S. L. Boye, S. B. Schwartz, S. Kaushal, A. J. Roman, J. J. Pang, A. Sumaroka, E. A. Windsor, J. M. Wilson, T. R. Flotte, G. A. Fishman, E. Heon, E. M. Stone, B. J. Byrne, S. G. Jacobson, W. W. Hauswirth, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U. S. A. 105, 15112-15117 (2008).
10. A. M. Maguire, K. A. High, A. Auricchio, J. F. Wright, E. A. Pierce, F. Testa, F. Mingozzi, J. L. Bennicelli, G. S. Ying, S. Rossi, A. Fulton, K. A. Marshall, S. Banfi, D. C. Chung, J. I. Morgan, B. Hauck, O. Zelenaia, X. Zhu, L. Raffini, F. Coppieters, E. De Baere, K. S. Shindler, N. J. Volpe, E. M. Surace, C. Acerra, A. Lyubarsky, T. M. Redmond, E. Stone, J. Sun, J. W. McDonnell, B. P. Leroy, F. Simonelli, J. Bennett, Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605 (2009).
11. R. E. MacLaren, R. A. Pearson, A. MacNeil, R. H. Douglas, T. E. Salt, M. Akimoto, A. Swaroop, J. C. Sowden, R. R. Ali, Retinal repair by transplantation of photoreceptor precursors. Nature 444, 203-207 (2006).
12. J. S. Meyer, R. L. Shearer, E. E. Capowski, L. S. Wright, K. A. Wallace, E. L. McMillan, S. C. Zhang, D. M. Gamm, Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A. 106, 16698-16703 (2009).
13. A. F. Wright, A searchlight through the fog. Nat. Genet. 17, 132-134 (1997).
14. S. Mohand-Said, D. Hicks, M. Simonutti, D. Tran-Minh, A. Deudon-Combe, H. Dreyfus, M. S. Silverman, J. M. Ogilvie, T. Tenkova, J. Sahel, Photoreceptor transplants increase host cone survival in the retinal degeneration (rd) mouse. Ophthalmic Res. 29, 290-297 (1997).
15. S. Mohand-Said, D. Hicks, H. Dreyfus, J. A. Sahel, Selective transplantation of rods delays cone loss in a retinitis pigmentosa model. Arch. Ophthalmol. 118, 807-811 (2000).
16. S. Mohand-Said, A. Deudon-Combe, D. Hicks, M. Simonutti, V. Forster, A. C. Fintz, T. Léveillard, H. Dreyfus, J. A. Sahel, Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse. Proc. Natl. Acad. Sci. U. S. A. 95, 8357-362 (1998).
17. A. C. Fintz, I. Audo, D. Hicks, S. Mohand-Said, T. Léveillard, J. Sahel, Partial characterization of retina-derived cone neuroprotection in two culture models of photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci. 44, 818-825 (2003).
18. C. Punzo, K. Kornacker, C. L. Cepko, Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat. Neurosci. 12, 44-52 (2009).
19. R. W. Oppenheim, The neurotrophic theory and naturally occurring motoneuron death. Trends Neurosci. 12, 252-255 (1989).
20. R. Adler, M. Hatlee, Plasticity and differentiation of embryonic retinal cells after terminal mitosis. Science 243, 391-393 (1989).
21. T. Léveillard, S. Mohand-Saïd, O. Lorentz, D. Hicks, A. C. Fintz, E. Clérin, M. Simonutti, V. Forster, N. Cavusoglu, F. Chalmel, P. Dollé, O. Poch, G. Lambrou, J. A. Sahel, Identification and characterization of rod-derived cone viability factor. Nat. Genet. 36, 755-759 (2004).
22. C. H. Lillig, A. Holmgren, Thioredoxin and related molecules- from biology to health and disease. Antioxid. Redox Signal. 9, 25-47 (2007).
23. X. W. Wang, Y. C. Liou, B. Ho, J. L. Ding, An evolutionarily conserved 16-kDa thioredoxin-related protein is an antioxidant which regulates the NF-kappaB signaling pathway. Free Radic. Biol. Med. 42, 247-259 (2007).
24. F. Chalmel, T. Léveillard, C. Jaillard, A. Lardenois, N. Berdugo, E. Morel, P. Koehl, G. Lambrou, A. Holmgren, J. A. Sahel, O. Poch, Rod-derived cone viability factor-2 is a novel bifunctional-thioredoxin-like protein with therapeutic potential. BMC Mol. Biol. 8, 74 (2007).
25. Y. Yang, S. Mohand-Said, A. Danan, M. Simonutti, V. Fontaine, E. Clerin, S. Picaud, T. Léveillard, J. A. Sahel, Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol. Ther. 17, 787-795 (2009).
26. F. C. Schlichtenbrede, A. MacNeil, J. W. Bainbridge, M. Tschernutter, A. J. Thrasher, A. J. Smith, R. R. Ali, Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther. 10, 523-527 (2003).
27. K. Pekkari, A. Holmgren, Truncated thioredoxin: Physiological functions and mechanism. Antioxid. Redox Signal. 6, 53-61 (2004).
28. T. Cronin, W. Raffelsberger, I. Lee-Rivera, C. Jaillard, M. L. Niepon, B. Kinzel, E. Clérin, A. Petrosian, S. Picaud, O. Poch, J. A. Sahel, T. Léveillard, The disruption of the rod-derived cone viability gene leads to photoreceptor dysfunction and susceptibility to oxidative stress. Cell Death Differ; Published online 5 February 2010 (10. 1038/cdd. 2010. 2).
29. K. Komeima, B. S. Rogers, L. Lu, P. A. Campochiaro, Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 103, 11300-11305 (2006).
30. R. Fridlich, F. Delalande, C. Jaillard, J. Lu, L. Poidevin, T. Cronin, L. Perrocheau, G. Millet-Puel, M. L. Niepon, O. Poch, A. Holmgren, A. Van Dorsselaer, J. A. Sahel, T. Léveillard, The thioredoxin-like protein rod-derived cone viability factor (RdCVFL) interacts with TAU and inhibits its phosphorylation in the retina. Mol. Cell. Proteomics 8, 1206-1218 (2009).
31. S. Reichman, R. K. Kalathur, S. Lambard, N. Aït-Ali, Y. Yang, A. Lardenois, R. Ripp, O. Poch, D. J. Zack, J. A. Sahel, T. Léveillard, The homeobox gene CHX10/VSX2 regulates RdCVF promoter activity in the inner retina. Hum. Mol. Genet. 19, 250-261 (2010).